2019
Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes
Wong W, Lowery M, Berger M, Kemel Y, Taylor B, Zehir A, Srinivasan P, Bandlamudi C, Chou J, Capanu M, Varghese A, Yu K, Iacobuzio‐Donahue C, Shia J, Klimstra D, Jarnagin W, Stadler Z, O’Reilly E. Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes. Cancer 2019, 125: 1441-1448. PMID: 30620386, PMCID: PMC6467723, DOI: 10.1002/cncr.31951.Peer-Reviewed Original ResearchConceptsPathogenic germline alterationsAmpullary carcinomaSomatic alterationsGermline testingSomatic testingMemorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer TargetsMemorial Sloan Kettering Cancer CenterDe-identified fashionMedian overall survivalPartial radiographic responseRare gastrointestinal cancerTargetable somatic alterationsGermline genetic alterationsSubtypes of ACOpt-in strategyRadiographic responseOverall survivalMSK-IMPACTClinicopathological featuresGermline alterationsClinical outcomesPathological subtypesGenetic alterationsClinical correlatesGastrointestinal cancer
2003
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial. JAMA 2003, 290: 2149-2158. PMID: 14570950, DOI: 10.1001/jama.290.16.2149.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerRadiographic tumor regressionPartial radiographic responseCell lung cancerRadiographic responseTumor regressionEpidermal growth factor receptorOral gefitinibLung cancerOral EGFR tyrosine kinase inhibitorRandomized phase 2 trialEGFR tyrosine kinase inhibitorsAcne-like rashCommunity oncology centersPhase 2 trialLung cancer symptomsPhase 1 trialEfficacy of gefitinibDisease-related symptomsFraction of patientsGrowth factor receptorNSCLC symptomsChemotherapy regimensEpidermal growth factor receptor tyrosine kinaseOverall survival
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply